1st December 2009
Aquapharm Strengthens Management Team with the Appointment of Research Director
Aquapharm Biodiscovery Ltd, a leading marine biotechnology company, is pleased to announce it has appointed Dr. Lloyd Payne as its Research Director. Lloyd has joined Aquapharm to drive forward the discovery and development of novel bioactives derived from the company's unique collection of marine micro-organisms. MORE>>
1st December 2009
Aquapharm Appoints Business Development Director
Aquapharm Biodiscovery Ltd, a leading marine biotechnology company, is pleased to announce the appointment of Jon Williams as Business Development Director. Jon's primary focus will be to drive forward the commercialisation of scientifically validated, sustainably sourced functional ingredients and industrial biotechnology products derived from Aquapharm's collection of marine micro-organisms. MORE>>
12th March 2009
Aquapharm Strengthens Management Team with Appointment of New Chairman and CFO
Aquapharm Biodiscovery, a leading marine biotechnology company, today announces the appointment of Steve Harris as non-executive Chairman of the board, with immediate effect. Mr. Harris replaces Ron James, the outgoing chairman, who is retiring. The Company also announces the appointment of Sandy McDougall as Chief Financial Officer. MORE>>
4th August 2008
Aquapharm and Croda International Sign Three Year Research Collaboration Agreement
Marine biotechnology company Aquapharm Biodiscovery Ltd and Croda International Plc today announced the signing of a collaboration and license agreement. The three-year collaboration will provide Croda with an exclusive license to novel marine derived natural products identified through the collaboration from strains from Aquapharm's proprietary microbial library for use in topical cosmetic applications in skin and hair care. MORE>>
July 9th 2008
Aquapharm and Dr. Reddy’s Sign Commercial License Agreements
Scottish marine biotechnology company Aquapharm Biodiscovery Limited today announced the signing of a new commercial license agreement and an extension of an existing research and development license agreement with Dr. Reddy’s Laboratories Limited. MORE>>
June 16th 2008
Aquapharm CEO wins Ernst & Young Scottish Entrepreneur of the Year in healthcare
The award recognises Dr Mearns Spragg's entrepreneurial ambition in setting up Aquapharm as well as his pioneering and innovative work in developing new anitbiotic compounds. MORE>>
May 2008
Aquapharm strengthens board and management team
Mr Douglas Thomson has been appointed as Aquapharm's new Commercial Director and Professor Axel Kleeman has joined the board as a Non-executive Director. MORE>>
Oct 15th 2007
Founder wins prestigious Gannochy Innovation Award
Dr Andrew Mearns Spragg, founder of Aquapharm has won Scotland's top award for Innovation from the Royal Society of Edinburgh. The Gannochy Innovation Award is an annual award which carries a prize of £50,000 along with a specially commissioned gold medal which will be used to further the development of the company's lead anti-infective candidates. MORE>>
July 24th 2007
Aquapharm secures second round investment of £4M
Aquapharm's technology has been backed by investments from Aescap Venture, Tate & Lyle Ventures along with further investments by Scottish Enterprise, NESTA and HIE Argyll and the Islands Enterprise. MORE>>
June 13th 2007
Nexxus
Aquapharm Bio-Discovery wins DTI support to search for anti-cancer agents from its diverse collection of marine microbes. MORE >>
2007
SIMS Conference
Aquapharm R&D Manager, Dorothee Gotz, is to present at the Society for Industrial Microbiology annual meeting in Denver on the Commercialisation of Extremophiles. MORE>>
May 6-8th 2007
Aquapharm Exhibits at Vitafoods
In partnership with Scottish Development International (SDI), Aquapharm exhibited at Vitafoods 2007 where significant interest was shown in its carotenoid and nutraceutical based research. MORE>>
2007
Aquapharm attracts Pharma interest at BIO
Aquapharm CEO, Andrew Mearns Spragg and Business Development Manager, Jason Cleaversmith took part in the bio-partnering events at BIO 2007 in Boston. Significant interest was shown in the developing pipeline of anti-microbial candidates, sourced from marine microbes, and the company now has a number of agreements in place to explore potential partnerships and development programmes for its drug leads.